Long-term effectiveness and safety of benralizumab in EGPA: a 3-year single-center experience.

ABSTRACT:

Objectives

Benralizumab emerged as a promising treatment option for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the long-term effectiveness and safety of benralizumab in patients with severe asthma and relapsing-refractory EGPA.

Methods

This retrospective, single-center study evaluated patients treated with benralizumab (30 mg/8 weeks), followed for up to 36 months. Primary outcome included disease remission (defined as Birmingham Vasculitis Activity Score version 3 = 0 and prednisone dose ≤4 mg/day). Secondary endpoints were corticosteroid tapering, lung function, relapses, treatment failure and drug retention rates.

Results

The study included 33 EGPA patients (17 [51.5%] male; median age at benralizumab initiation 56 years [IQR: 47-62])

SUBMITTER: Davanzo F 

PROVIDER: S-EPMC12584834 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature